Meeting
2023 ASCO Annual Meeting
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
Authors
Catherine Callaghan Coombs
UCI Health, Orange, CA
Catherine Callaghan Coombs , Nirav Niranjan Shah , Wojciech Jurczak , Jennifer Ann Woyach , Chan Cheah , Krish Patel , Kami J. Maddocks , Yucai Wang , Catherine E. Muehlenbein , Chunxiao Wang , Sarang Abhyankar , Donald Edward Tsai , Toby A. Eyre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT03740529
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7513)
DOI
10.1200/JCO.2023.41.16_suppl.7513
Abstract #
7513
Poster Bd #
64
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
First Author: Joseph McGuirk
Poster
2021 ASCO Annual Meeting
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.
First Author: Sumanta K. Pal
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2024 ASCO Annual Meeting
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.
First Author: Yu Chen